Literature DB >> 2154331

Generation of cell-mediated cytotoxicity against bovine-papilloma-virus-transformed primary mouse cell lines.

A Laatikainen1, H Karjalainen, H Sarkkinen, K Syrjänen, R Mäntyjärvi.   

Abstract

The immunogenicity and immunosensitivity of primary mouse cell lines transformed by bovine papilloma virus 1 (BPV1) DNA were studied in a syngeneic mouse model by determining cell-mediated cytotoxicity in the spleens of mice immunized with the transformed cells. One of the cell lines induced the generation of cell-line-specific Thy1.2-positive cytotoxic effector cells. However, most of the cell lines tested induced the generation of Thy1.2-positive effector cells, which in addition to BPV1-transformed cells were able to lyse a syngeneic cell line transformed by methylcholanthrene. The lysis of BPV1- and methylcholanthrene-transformed cell lines was mediated by recognition of the same antigenic determinants expressed on these cells, and all the BPV1-transformed cell lines were sensitive to lysis by these nonspecific effector cells of the lymphokine-activated killer (LAK) type.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154331     DOI: 10.1007/BF01786884

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Macrophage-resistant murine simian virus 40 tumors express a retroviral type-specific gp70.

Authors:  S K Chapes; A E O'Neill; L Flaherty; L R Gooding
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

2.  Antigenic similarity between plasma membrane proteins of fetal hamster cells and simian virus 40 tumor surface antigens.

Authors:  W A Weppner; J H Coggin
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

3.  Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: a caveat for the interpretation of experiments done under "syngeneic" conditions.

Authors:  P Golstein; M F Luciani; H Wagner; M Röllinghoff
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

Review 4.  The murine antitumor immune response and its therapeutic manipulation.

Authors:  R J North
Journal:  Adv Immunol       Date:  1984       Impact factor: 3.543

5.  Cell-mediated immunity in wart infection.

Authors:  J Thivolet; J Viac; M J Staquet
Journal:  Int J Dermatol       Date:  1982-03       Impact factor: 2.736

Review 6.  Immunological aspects of wart regression with special reference to regression phenomenon of numerous flat warts. An experiment on tumor immunity in man by nature.

Authors:  H Tagami; M Oguchi; S Ofuji
Journal:  J Dermatol       Date:  1983-02       Impact factor: 4.005

7.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

8.  Forssman antigen in BK virus-induced tumor cell lines.

Authors:  H E Karjalainen; R A Mäntyjärvi
Journal:  Acta Pathol Microbiol Scand C       Date:  1981-02

9.  Tumorigenicity of primary mouse fibroblasts transformed by bovine papillomavirus type 1.

Authors:  R Mäntyjärvi; H Sarkkinen; S Parkkinen; A Laatikainen; A Ryhänen; K Syrjänen
Journal:  Intervirology       Date:  1988       Impact factor: 1.763

10.  Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression.

Authors:  H zur Hausen
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

View more
  2 in total

1.  Tumorigenicity and H-2 expression of papillomavirus-transformed mouse cell lines.

Authors:  A Laatikainen; H Karjalainen; H Jägerroos; H Sarkkinen; R Mäntyjärvi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Effect of interferon gamma on the sensitivity of bovine-papilloma-virus(BPV1)-transformed cell lines to cell-mediated cytotoxicity.

Authors:  A Laatikainen; L Schultz-Suhonen; R Mäntyjärvi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.